Analysis of safety data in children after receiving two doses of ProQuad® (MMRV).

Stephanie O Klopfer,Jon E Stek,Maria Petrecz,Keith S Reisinger,Steven B Black,Michelle G Goveia,Ouzama Nicholson,Julie L Gardner,Anthony D Grosso,Michelle L Brown,Barbara J Kuter,Florian P Schödel

Vaccine（2014）

引用 13|浏览7

暂无评分

摘要

•This paper describes the safety of a 2-dose regimen of MMRV.•A 2-dose regimen of MMRV has an acceptable safety profile in children 12–23 months old.•These data support the current prescribing information for MMRV.1ON was employed by Merck at the time of this research. She is now employed by GlaxoSmithKline.2FS was employed by Merck at the time of this research. He is now owner of Philimmune LLC.

查看译文

关键词

Safety,MMRV,ProQuad®,Integrated analyses,Tolerability

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要